Evoke Security Selected for Google's Inaugural Gemini Startup Forum: Cybersecurity
Delivered by Google for Startups in partnership with Google DeepMind, Google Cloud, Mandiant, VirusTotal, and Wiz, the Forum connects a select group of cybersecurity founders with the AI and security specialists building these technologies at Google. This year's inaugural cohort was organized into six specialized focus areas, with Evoke Security being selected in the AI agent security and governance category, alongside other leading startups addressing the security challenges posed by agents entering enterprise environments.
"Every enterprise is working through how they secure a workforce that's increasingly not human," said
Evoke's selection reflects the industry's shift from perimeter defense toward securing autonomous AI agents, with an emphasis on enterprise governance and the safe deployment of self-governing systems. Selection into the Forum adds to a strong start to the year for Evoke, which was also chosen for the 2026 CrowdStrike, AWS, and NVIDIA Cybersecurity Startup Accelerator and was a finalist in the CrowdStrike Startup Nest.
For more information on the Forum and the full cohort, read the Google Cloud announcement.
About Evoke Security
Evoke Security is a leading AI detection and response platform purpose-built to secure AI agents. Founded by incident response veterans, Evoke's Agentic AI-powered platform enables security teams to continuously inventory, threat model, and monitor AI agents. Evoke treats agents as the next operating system for businesses, surfacing risky configurations and analyzing real-time behavior and actions to enforce strict controls, ensuring businesses can innovate without compounding security debt.
View original content to download multimedia:https://www.prnewswire.com/news-releases/evoke-security-selected-for-googles-inaugural-gemini-startup-forum-cybersecurity-302825119.html
SOURCE Evoke Security
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Profition Reviews: Should You Trust Profition AI Trading System in 2026?
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share